Cargando…

Radioiodine Thyroid Remnant Ablation after Recombinant Human Thyrotropin or Thyroid Hormone Withdrawal in Patients with High-Risk Differentiated Thyroid Cancer

To supplement limited relevant literature, we retrospectively compared ablation and disease outcomes in high-risk differentiated thyroid carcinoma (DTC) patients undergoing radioiodine thyroid remnant ablation aided by recombinant human thyrotropin (rhTSH) versus thyroid hormone withdrawal/withholdi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Pitoia, Fabián, Marlowe, Robert J., Abelleira, Erika, Faure, Eduardo N., Bueno, Fernanda, Schwarzstein, Diego, Lutfi, Rubén Julio, Niepomniszcze, Hugo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Hindawi Publishing Corporation 2012
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3529433/ https://www.ncbi.nlm.nih.gov/pubmed/23304637 http://dx.doi.org/10.1155/2012/481568

Ejemplares similares

Dynamic risk allows us to adequately select patients with differentiated thyroid cancer who do not require radioiodine treatment
por: Abelleira, Erika, et al.
Publicado: (2021)

Thyroid cancer in the Era of COVID-19
por: Smulever, Anabella, et al.
Publicado: (2020)

Adjuvant treatment with thyrotropin alpha for remnant ablation in thyroid cancer
por: Biondi, Bernadette, et al.
Publicado: (2009)

The Effectiveness of Recombinant Human Thyroid-Stimulating Hormone versus Thyroid Hormone Withdrawal Prior to Radioiodine Remnant Ablation in Thyroid Cancer: A Meta-Analysis of Randomized Controlled Trials
por: Pak, Kyoungjune, et al.
Publicado: (2014)

New approaches for patients with advanced radioiodine-refractory thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2022)

Clinical Outcome of Remnant Thyroid Ablation with Low Dose Radioiodine in Korean Patients with Low to Intermediate-risk Thyroid Cancer
por: Ha, Seunggyun, et al.
Publicado: (2015)

Dramatic clinical response to dabrafenib plus trametinib in anaplastic thyroid carcinoma and the challenges faced during the COVID-19 pandemic
por: Bueno, Fernanda, et al.
Publicado: (2021)

Scintigraphic evaluation of salivary gland function in thyroid cancer patients after radioiodine remnant ablation
por: Krčálová, Eva, et al.
Publicado: (2020)

Assessment of Different Radioiodine Doses for Post-ablation Therapy of Thyroid Remnants: A Systematic Review
por: Ansari, Mojtaba, et al.
Publicado: (2022)

Regional Variation across Canadian Centers in Radioiodine Administration for Thyroid Remnant Ablation in Well-Differentiated Thyroid Cancer Diagnosed in 2000–2010
por: Rachinsky, I., et al.
Publicado: (2016)

Low versus high radioiodine activity for ablation of the thyroid remnant after thyroidectomy in Han Chinese with low-risk differentiated thyroid cancer
por: Lv, Rong-Bin, et al.
Publicado: (2017)

Economic Evaluation of Recombinant Human Thyroid Stimulating Hormone Stimulation vs. Thyroid Hormone Withdrawal Prior to Radioiodine Ablation for Thyroid Cancer: The Korean Perspective
por: Sohn, Seo Young, et al.
Publicado: (2015)

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Patients with Metastatic Differentiated Thyroid Carcinoma
por: Zagar, Ivana, et al.
Publicado: (2012)

Radioiodine remnant ablation in stage I adult papillary thyroid carcinoma: does it improve postoperative outcome?
por: Hay, Ian D, et al.
Publicado: (2022)

Diagnosis and Treatment of Acute Pleural Effusion following Radioiodine Remnant Ablation Post Lobectomy for Thyroid Cancer
por: Qiu, Xian, et al.
Publicado: (2022)

Assessment of three different radioiodine doses for ablation therapy of thyroid remnants: Efficiency, complications and patient comfort
por: Soyluoglu, Selin, et al.
Publicado: (2023)

SAT525 Long-Term Outcomes in Stage I Thyroid Cancer Without Radioiodine Remnant Ablation
por: Mubeen, Faiza, et al.
Publicado: (2023)

MON-LB87 Recombinant Human TSH vs Thyroid Hormone Withdrawal Preparation for Radioiodine Ablation in Pediatric Differentiated Thyroid Cancer
por: Schumm, Max A, et al.
Publicado: (2020)

Effectiveness of Different Thyroid Stimulating Hormone Thresholds for Thyroid Hormone Withdrawal - Aided Radioiodine Ablation in Patients With Differentiated Thyroid Cancer: A Systematic Review and Meta - Analysis
por: Rojas, Tatiana, et al.
Publicado: (2021)

A pre-ablative thyroid-stimulating hormone with 30–70 mIU/L achieves better response to initial radioiodine remnant ablation in differentiated thyroid carcinoma patients
por: Xiao, Juan, et al.
Publicado: (2021)

Radioiodine Thyroid Ablation in Graves’ Hyperthyroidism: Merits and Pitfalls
por: Nwatsock, J. F., et al.
Publicado: (2012)

Radioiodine thyroid remnant ablation in patients with differentiated thyroid carcinoma (DTC): prospective comparison of long-term outcomes of treatment with 30, 60 and 100 mCi
por: Kukulska, Aleksandra, et al.
Publicado: (2010)

Thyroid remnant ablation with radioiodine activity of 30, 60, and 100 mCi in patients with differentiated thyroid cancer – a prospective comparison of long-term outcomes
por: Kukulska, Aleksandra, et al.
Publicado: (2020)

Radioiodine remnant ablation of differentiated thyroid cancer does not further increase oxidative damage to membrane lipids - early effect
por: Makarewicz, Jacek, et al.
Publicado: (2010)

Recombinant Human Thyrotropin-Aided Radioiodine Therapy in Tracheal Obstruction by an Invading Well-Differentiated Thyroid Carcinoma
por: Pontikides, Nickolaos, et al.
Publicado: (2013)

Molecular evidence reveals thyrotropin intervention enhances the risk of developing radioiodine-refractory differentiated thyroid carcinoma
por: Samimi, Hilda, et al.
Publicado: (2022)

Myopathy following postoperative ablative radioiodine for follicular carcinoma of the thyroid
por: Price, Hermione C, et al.
Publicado: (2009)

Radioiodine remnant ablation in low-risk differentiated thyroid cancer patients who had R0 dissection is an over treatment
por: Bal, Chandrasekhar, et al.
Publicado: (2015)

The Association of Thyrotropin and Autoimmune Thyroid Disease in Developing Papillary Thyroid Cancer
por: Lee, I-Shuan, et al.
Publicado: (2017)

Dabrafenib plus trametinib treatment in patients with anaplastic thyroid carcinoma: an Argentinian experience
por: Bueno, Fernanda, et al.
Publicado: (2023)

Radioiodine Remnant Ablation: A Critical Review
por: Bal, Chandra Sekhar, et al.
Publicado: (2015)

The role of Hashimoto thyroiditis in predicting radioiodine ablation efficacy and prognosis of low to intermediate risk differentiated thyroid cancer
por: Albano, Domenico, et al.
Publicado: (2021)

The Usefulness of Thyroid Antibodies in the Diagnostic Approach to Autoimmune Thyroid Disease
por: Vargas-Uricoechea, Hernando, et al.
Publicado: (2023)

Clinical Outcomes after Early and Delayed Radioiodine Remnant Ablation in Patients with Low-Risk Papillary Thyroid Carcinoma: Propensity Score Matching Analysis
por: Ahn, Jonghwa, et al.
Publicado: (2020)

Selective use of sorafenib in the treatment of thyroid cancer
por: Pitoia, Fabián, et al.
Publicado: (2016)

Redifferentiating Thyroid Cancer: Selumetinib-enhanced Radioiodine Uptake in Thyroid Cancer
por: Larson, Steven M., et al.
Publicado: (2017)

Thyrotropin serum levels and coexistence with Hashimoto’s thyroiditis as predictors of malignancy in children with thyroid nodules
por: Zirilli, Giuseppina, et al.
Publicado: (2019)

Thyroid hormone receptor β sumoylation is required for thyrotropin regulation and thyroid hormone production
por: Ke, Sujie, et al.
Publicado: (2021)

Heath-related quality of life in thyroid cancer patients following radioiodine ablation
por: Taïeb, David, et al.
Publicado: (2011)

Efficacy and Affecting Factors of (131)I Thyroid Remnant Ablation After Surgical Treatment of Differentiated Thyroid Carcinoma
por: Wang, Chen, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_5idk45amvgh5rpll7uf1n0q8js